Latest Asx Healthcare Stocks News

Emyria’s new treatment-resistant depression program shows statistically significant symptom improvements in a small initial cohort, expanding its mental health therapy offerings beyond PTSD.

Acrux has amended its licensing agreement with Gedeon Richter to bring its Estradiol spray Lenzetto® to Australia, unlocking up to AUD 5.4 million in milestone payments and addressing a critical shortage in Menopause Hormone Therapy products.

Vitasora has launched its proprietary vCare EMR platform, cutting SaaS costs by over 90% and nearly doubling patient enrolments in April. The company targets cashflow breakeven in H2 2026 as enrolment momentum builds.

Nexalis Therapeutics has advanced its IRX-211 program by screening the first patient in a pivotal Phase 2 trial for Breakthrough Cancer Pain, aiming to address a significant unmet need in oncology supportive care.

Pro Medicus has secured a 5-year, A$37 million contract renewal with Northwestern Medicine, featuring higher minimum usage commitments and increased fees per transaction, reflecting growth in exam volumes.

InhaleRx has secured swift Human Research Ethics Committee approval for its redesigned IRX-211 Phase 2 trial, expanding participant numbers and potentially bypassing Phase 3 to speed market entry.